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S306 Poster Session IIadjuvant anti-tumor effect of PSA-specific T cells. This report pres-
ents a novel treatment approach involving allogeneic SCT in pros-
tate cancer patients who do not respond to chemotherapy and/or
cannot undergo prostectomy.403
PERIPHERAL BLOOD STEM CELLS AND GRANULOCYTE COLONY-STIMU-
LATING FACTOR ARE ASSOCIATED WITH ACUTE GRAFT-VERSUS-HOST
DISEASE
Ringden, O., Remberger, M. Karolinska Institutet, Karolinska University
Hospital Huddinge, Stockholm, Sweden
Does granulocyte colony-stimulating factor (G-CSF) increases
GVHD or not? A mouse model of GVHD showed that G-CSF in-
duce GVHD after bone marrow (BM) transplantation (Morris et al,
Nature Med 15:436, 2009). Total body irradiation (TBI) increased
G-CSF receptors on host dendritic cells, stimulating acute GVHD.
Their report prompted us to reassess the role of G-CSF prophy-
laxis in our HSCT patients. During 1994–2002, 260 patients
were given G-CSF prophylaxis. Patients not given G-CSF
(n5 205) who underwent HSCT from 1993 to 2003 were controls.
We included all patients receiving BM (n5 286) or peripheral
blood stem cell (PBSC) grafts (n5 179) from HLA-identical sib-
lings (n5 225) or HLA-A, -B, or DRß1 genomically identical un-
related donors (MUDs; n5 240). The G-CSF group had more
MUD transplants, fewer patients receiving reduced-intensity con-
ditioning (RIC), more patients receiving antithymocyte globulin
(p\0.001), and AB0 mismatch was commoner (p5 0.03). Patients
treated with G-CSF had acute GVHD (grades II–IV) of 29%, vs.
19% in the controls (p\0.01). GVHD occurred in 33% of pa-
tients given PBSC, as compared to 19% of those given BM
(p\0.001). There was no significant difference in incidence of
GVHD between HLA-identical sibling transplants and MUD
transplants, between those with myeloablative conditioning and
those with RIC, or between those treated with TBI and chemother-
apy and those treated with chemotherapy only. In patients condi-
tioned with chemotherapy, 34% in the G-CSF group developed
acute GVHD as compared to 21% in the controls (p5 0.035). In
patients treated with TBI, those given G-CSF had an incidence
of acute GVHD (grades II–IV) of 26% as opposed to 17% in the
controls (p5 0.10). In PBSC recipients, 39% in the G-CSF group
developed acute GVHD as compared to 24% in the controls
(p5 0.025). In recipients of BM, the corresponding figures were
22% and 15%, respectively, in the two groups (p5 0.19). In the
present study, a multivariate analysis showed that acute GVHD
of grades II–IV was associated with PBSC grafting (hazards ratio
(HR)5 2.29, p\0.0001), female donors (HR5 1.74, p5 0.005),
major AB0 mismatch (HR5 1.58, p5 0.03), and
G-CSF (HR5 1.52, p5 0.03). Differences were adjusted. There
were no differences between the two groups regarding non-relapse
mortality, relapse, and survival.
Conclusion: G-CSF induces GVHD in mice, but differs compared
to humans regarding the role of source of stem cell and conditioning
regimen.404
SIROLIMUS, TACROLIMUS, AND RABBIT ATG (RATG) AS GRAFT-VERSUS-
HOST PROPHYLAXIS IN PATIENTS UNDERGOING UNRELATED DONOR
HEMATOPOIETIC STEM CELL TRANSPLANT (HCT)
Khaled, S.K., Palmer, J., Parker, P., Nademanee, A., Pullarkat, V.,
Cai, J.-L., Snyder, D., Karanes, C., Senitzer, D., Forman, S.,
Nakamura, R. City of Hope, Duarte, CA
The use of sirolimus combined with tacrolimus +/- low-dose
methotrexate (MTX) recently showed a promising result in pre-
venting acute GVHD after unrelated donor HCT (Antin et al.
Blood 2003) although a significant number of patients still experi-
enced chronic GVHD. In an attempt to further improve the out-
come, we have developed a novel combination of tacrolimus (FK),
sirolimus (SIR) and r-ATG +/- MTX (MTX given for patients
with a mismatch donor) and studied in a total of 51 patients
who underwent unrelated donor HCT from 7/5/2006 to 7/31/2009. The median age at transplant was 56 (range: 16 -71).
Twenty were female and 31 were male. Indications for transplant
were as follows: ALL (n5 12, CR1/25 11, Induction Failure5 1),
AML (n5 19: CR1/25 12: relapse/induction failure5 7), CML
(n5 4: CP1/25 2, AP/BC5 2), non-Hodgkin Lymphoma
(n5 5); CLL (n5 1), MDS (n5 8), MPD (n5 2). Thirty one pa-
tients received reduced-intensity conditioning (fludarbine/melpha-
lan [Flu/Mel]) and 20 received full-intensity conditioning (FTBI/
VP-16: n5 13, FTBI/Cytoxan: n5 7). All received PBSC graft ex-
cept for two patients who received bone marrow graft. Twenty-
nine of 51 patients had a 10/10-match donor by high resolution
HLA typing. Engraftment rate was 92.2% (n5 47) with the me-
dian neutrophil engaftment at 15 days (range: 10-39). Eighteen
patients (38% of 47 engrafted) developed grade II-IV acute
GVHD (grade III5 3, grade IV5 0). Chronic GVHD developed
in 21 of 37 evaluable patients (57%, limited n5 7, extensive
n5 14). We observed TTP/HUS in 10 patients (20%) and one
case of VOD. Eighteen (42%) of 43 patients at risk (R+ or D+)
developed CMV reactivation, while 10 patients developed EBV re-
activation (19.6%). After a median follow up of 11 months (range:
2-35) 38 patients were alive. The 1-year probabilities of overall
survival, disease-free survival (DFS), and relapse rate were 74.7%
(63-83%), 73.2% (62-82%), and 11% (5-25%), respectively.
Non-relapse mortality was 14.7% (8-26%) at 100 day and
17.5% (10-29%) at 1 year. There were no significant differences
in the outcomes according to conditioning regimens, although
there was a trend for lower NRM with Flu/Mel (11% vs. 27%
at 1 year, p5 0.1).
In summary FK/SIR combined with r-ATG +/- MTX is associ-
ated with a promising early result in GVHD prevention and survival
in this high-risk population. However, the rate of graft failure (n5 4)
appeared greater than our historic data, which is being further inves-
tigated at our institution.405
PROGRESSIVE IMPROVEMENT IN STEROID-REFRACTORY/DEPENDENT/
INTOLERANT CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE
(CGVHD) FOLLOWING A 24-WEEK COURSE OF EXTRACORPOREAL
PHOTOPHERESIS (ECP)
Greinix, H.T.1, van Besien, K.2, Elmaagacli, A.3, Hillen, U.3,
Knobler, R.1, Parenti, D.4, Reddy, V.5, Michallet, M.6,
Flowers,M.E.D.7 1Medical University of Vienna, Vienna, Austria; 2Uni-
versity of Chicago, IL; 3Universitaetsklinikum Essen, Essen, Germany;
4Therakos Inc, Raritan, NJ; 5Florida Hospital Cancer Institute, Gaines-
ville, FL; 6Hospital Edouard Herriot, Lyon, France; 7Fred Hutchinson
Cancer Center and University of Washington, Seattle, WA
In a previously reported multicenter randomized standard-ther-
apy controlled trial, a 12-week course of ECP resulted in several
beneficial outcomes in patients (pts) with steroid-refractory/intol-
erant/dependent cGVHD. (Flowers et al, Blood 112:2667-74.
2008). We conducted an open-label cross-over extension study
to provide access to ECP for participants in the standard of care
arm of this randomized study and enrolled 29 pts. ECP was ad-
ministered 3 times during week 1, 2 treatments weekly until
week 12 then 2 treatments until week 24. The median age of the
study cohort was 43 (20-67) years and 26 pts (90%) had extensive
cGVHD. Onset was de novo in 11 (37.9%), progressive in 15
(51.7%) and quiescent in 3 (10.3%). Twenty-five of 29 pts
(86%) completed the 24 week course of ECP open-label treat-
ment. Causes for not completing the 24-weeks were GVHD pro-
gression (n5 2), 1 suicide, and 1 withdrawal of consent. Mean
daily steroid dose was 18.4 mg at the first ECP visit in this exten-
sion study (baseline). The median total skin score (TSS) was 7.8
(1.0-18.5) at the start of this cross-over extension study. The me-
dian percent change in TSS from baseline to week 12 and week 24
was -8.0 and -22.7, respectively. Four pts (14%) and 7 pts (24%)
achieved a $50% reduction in steroid dose at weeks 12 and 24, re-
spectively. In 4 pts (14%) and 8 pts (28%) a $50% reduction in
steroid dose and a final steroid dose of\10 mg/day at weeks 12
and 24 was obtained respectively. Complete or partial skin
response at week 24 was observed in 4 pts (14%) by investigator
assessment.
Poster Session II S307Conclusions: Progressive improvement in cutaneousmanifestations
of cGVHD was observed following a 24-week course of ECP in pts
who previously had exhibited no clinical response or worsening of
cGVHD while receiving standard immunosuppressive therapy
with corticosteroids. ECP improved skin GVHD and allowed for ta-
pering of corticosteroid doses to ‘‘low risk’’ levels of\10 mg predni-
sone-equivalents/day.406
NON-HEMATOPOIETIC ANTIGEN BLOCKS EARLY MEMORY IMPRINTING
OF GRAFT-VERSUS-HOST REACTIVE CD8 CELLS
Flutter, B.1, Fallah-Arani, F.1, Sivakumaran, S.1, Bennett, C.L.1,
Freeman, G.2, Sykes, M.3, Charaverty, R.1 1University College London,
London, United Kingdom; 2Harvard Medical School, Boston, MA; 3Har-
vard Medical School, Boston, MA
DonorTcell alloreactivity canbe co-opted todeliver a graft-versus-
tumor (GVT) response following blood or bone marrow transplanta-
tion (BMT). However, the major reason for treatment failure
following BMT is tumor recurrence, suggesting a long-term failure
of GVT immunity. In this study, we have considered the role of
non-hematopoietic antigen indetermining the fate of donorCD8cells
in a model of delayed DLI to partially MHC-mismatched chimeras,
where antigen was either expressed ubiquitously or restricted to the
hematopoietic compartment.We observed that donorCD8 cytotoxic
and cytokine responses were poorly sustained (at .8 weeks) in the
presence of non-hematopoietic antigen and this was associated with
a failure to establish a central memory (TCM) population. This effect
occurred at two distinct levels. Firstly, residual donor CD8 cells dem-
onstrated a classic PD-1highCD127low ‘exhaustion’ signature and con-
sistent with this, CD8 functionswere partially restored by blockade of
the PD-1 pathway. Secondly, during the initial phase of the primary
response (at day 5-8 following transfer ofCFSE-labelled splenocytes),
we observed that the proportion of post-mitotic, CFSElow CD8 cells
expressing a CD44highCD62Lhigh phenotype was much lower in chi-
meras where antigen was ubiquitous. These findings suggested the
possibility that early CD8 encounter with non-hematopoietic antigen
might severely disable memory precursor formation during the initial
phase of the response. In order to test this concept, we purifiedCD8 T
cells using congenic markers from the two sets of chimeras 14 days af-
ter initial T cell transfer, and then parked them in secondary, antigen
free hosts. After 21 days, we tested recall responses to alloantigen.We
found that priming in the presence of non-hematopoietic antigen se-
verely impaired the establishment of recall immunity in the absence of
antigen. Furthermore, while a significant proportion of CD8 T cells
primed in the absence of non-hematopoietic antigenhad a (TCM) phe-
notype in secondary hosts, this population was almost entirely absent
when initial priming occurred in primary hosts where antigen was
ubiquitous. These data demonstrate that alloantigen within non-he-
matopoietic tissues is not ignored, but rather actively inhibits both
the formation and maintenance of CD8 T cell memory. While these
effectsmay lessen the risk ofGVHD, theymight also impair the dura-
bility of the GVT response.407
TRAIL/DR5 INTERACTIONS ARE IMPORTANT FOR MEDIATING THYMIC
DAMAGE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION
Lu, S.X.1, Na, I.-K.1, Yim, N.1, Goldberg, G.L.1, Tsai, J.1, Rao, U.K.1,
Smith, M.1, King, C.G.1, Suh, D.1, Hirschorn-Cymerman, D.1,
Palomba, M.L.1, Penack, O.1, Holland, A.M.1, Jenq, R.R.1, Ghosh, A.1,
Tran, H.1, Merghoub, T.1, Sempowski, G.2, Ventevogel, M.2,
Beauchemin, N.3, van den Brink, M.R.M.1 1Memorial Sloan-Kettering
Cancer Center, New York, NY; 2Duke University School of Medicine,
Durham, NC; 3McGill University, Goodman Cancer Centre, Montreal,
QC, Canada
Thymic GVHD (tGVHD) is associated with prolonged immuno-
deficiency. We previously found that thymic output after allo-BMT
is directly related to thymus size, and inversely related to donor T
cell dose and GVHD severity. Additionally, radiation-containing
preparative regimens upregulate the death receptors Fas and DR5
on thymic stroma and decrease expression of cFLIP, thus sensitizing
the thymus to GVHD. Finally, very few donor alloreactive T cellsare sufficient to cause tGVHD via the Fas/Fas ligand (FasL) and
TRAIL/DR5 pathways.
Here, we performed allo-BMT in MHC-mismatched and
MHC-matched minor antigen-disparate model systems, and dem-
onstrated the exquisite sensitivity of the thymus to as few as
1-2.5105 donor T cells, which mediated tGVHD without sig-
nificant clinical GVHD. Additionally, tGVHD is partially revers-
ible in our models (contingent on low T cell dose), such that
mice with tGVHD exhibit a partial recovery in thymic cellularity
late (day 60) post-transplant.
We further studied the role of TRAIL in tGVHD, by asking
whether alloreactive T cells and GVHD or conditioning-associated
inflammation were strictly required for TRAIL/DR5-mediated
damage. We treated recipients of T cell-depleted allo-BMT with
mDR5-1 agonistic antibody either in the ‘‘early’’ peri-transplant pe-
riod, or ‘‘late,’’ in the second week post-transplant.
Allo-BMT recipients treated ‘‘early’’ with mDR5-1 had signifi-
cantly decreased thymic cellularity and splenic BM-derived T cells
as comparedwith controls. Furthermore, we observed similar BMcel-
lularity and BM-derived lineage- sca-1+ckit+ (LSK), all in the absence
of donor alloreactive T cells or GVHD. We observed similar results
with mice treated with ‘‘late’’ mDR5-1, indicating the continued sen-
sitivity of the thymus to TRAIL throughout the post-transplant pe-
riod, and that GVHD and/or conditioning-associated cytokines are
not required to enable TRAIL-mediated damage to the thymus.
Furthermore, we observed that on day 28 after T cell-depleted
allo-BMT, only 1-2% of donor thymocytes expressed DR5, suggest-
ing that mDR5-1 (and potentially TRAIL) mediate their effects on
thymic cellularity and function primarily via an indirect mechanism.
We conclude that the thymus is highly sensitive toGVHDand en-
dures severe damage at low levels of systemic GVHD. Furthermore,
we provide significant additionalmechanistic insight into the tempo-
ral, cellular, and inflammatory requirements for TRAIL/DR5medi-
ated damage to the thymus.408
P-SELECTIN REGULATES LEUKOCYTE TRAFFICKING AND EXPERIMEN-
TAL GRAFT-VERSUS-HOST-DISEASE AFTER ALLOGENEIC BONEMARROW
TRANSPLANTATION
Lu, S.X., Palomba, M.L., Na, I.-K., Terwey, T.H., Alpdogan, O.,
Bautista, J.L., Smith, M., Suh, D., King, C.G., Rao, U.K., Yim, N.,
Jenq, R.R., Zakrzewski, J.L., Holland, A.M., Penack, O., Dykstra, L.,
Bampoe, K., van den Brink, M.R.M. Memorial Sloan-Kettering Cancer
Center, New York, NY
P-selectin is found on most inflamed endothelium and interacts
with multiple leukocyte ligands. We found that P selectin-/- recipi-
ents of allogeneic bone marrow transplantation (allo-BMT) had sig-
nificantly less GVHD mortality and morbidity, as well as decreased
GVHD of the skin, liver and small bowels. This was associated with
diminished infiltration of alloactivated T cells into the Peyer’s
Patches and small bowels, coupled with increased numbers of donor
T cells in the spleen and secondary lymphoid organs (SLO) on day
14 and day 35 post-transplant. However, donor alloreactive T cells
inWT and P-selectin-/- allo-BMT recipients had similar alloactiva-
tion and apoptosis, and donor alloactivated T cells from WT and
P-selectin-/- allo-BMT recipients with GVHD showed similar pro-
liferation in vitro in a mixed leukocyte reaction, suggesting that the
inflammatory environment in WT and P-selectin-/- recipients was
comparable.
P-selectin glycoprotein ligand 1 (PSGL1) is the best-described
P-selectin ligand, and we then tested the role of PSGL1-/- donor al-
loreactive T cells in mediating GVHD. To our surprise, allo-BMT
recipients of WT and PSGL1-/- donor T cells had comparable sur-
vival and clinical GVHD scores, and further analyses on day 14 post-
transplant revealed similar numbers of donor alloactivated T cells in
the spleen, liver, mesenteric and peripheral lymph nodes, and Peyer’s
Patches. Additionally,WT and PSGL1-/- donor T cells had compa-
rable proliferation as measured by CFSE dilution, and comparable
alloactivation in vivo as determined by levels of CD25, CD44, and
CD62L.
We then asked whether PSGL1-/- T cells might display other P-se-
lectin ligands. Flow cytometric analyses of T cells from non-trans-
planted PSGL1-/- mice, and analyses of PSGL1-/- alloactivated T
